220 related articles for article (PubMed ID: 23926379)
1. Wnt signaling in bone.
Kubota T; Michigami T; Ozono K
Clin Pediatr Endocrinol; 2010 Jul; 19(3):49-56. PubMed ID: 23926379
[TBL] [Abstract][Full Text] [Related]
2. Wnt signaling in bone metabolism.
Kubota T; Michigami T; Ozono K
J Bone Miner Metab; 2009; 27(3):265-71. PubMed ID: 19333681
[TBL] [Abstract][Full Text] [Related]
3. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone.
Williams BO; Insogna KL
J Bone Miner Res; 2009 Feb; 24(2):171-8. PubMed ID: 19072724
[TBL] [Abstract][Full Text] [Related]
4. New Insights into Wnt-Lrp5/6-β-Catenin Signaling in Mechanotransduction.
Kang KS; Robling AG
Front Endocrinol (Lausanne); 2014; 5():246. PubMed ID: 25653639
[TBL] [Abstract][Full Text] [Related]
5. Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone.
Tu X; Delgado-Calle J; Condon KW; Maycas M; Zhang H; Carlesso N; Taketo MM; Burr DB; Plotkin LI; Bellido T
Proc Natl Acad Sci U S A; 2015 Feb; 112(5):E478-86. PubMed ID: 25605937
[TBL] [Abstract][Full Text] [Related]
6. The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.
Yorgan TA; Peters S; Jeschke A; Benisch P; Jakob F; Amling M; Schinke T
J Bone Miner Res; 2015 Jul; 30(7):1175-83. PubMed ID: 25640331
[TBL] [Abstract][Full Text] [Related]
7. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway.
Kamiya N; Ye L; Kobayashi T; Mochida Y; Yamauchi M; Kronenberg HM; Feng JQ; Mishina Y
Development; 2008 Nov; 135(22):3801-11. PubMed ID: 18927151
[TBL] [Abstract][Full Text] [Related]
8. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.
Choi HY; Dieckmann M; Herz J; Niemeier A
PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252
[TBL] [Abstract][Full Text] [Related]
9. New explanation for autosomal dominant high bone mass: Mutation of low-density lipoprotein receptor-related protein 6.
Whyte MP; McAlister WH; Zhang F; Bijanki VN; Nenninger A; Gottesman GS; Lin EL; Huskey M; Duan S; Dahir K; Mumm S
Bone; 2019 Oct; 127():228-243. PubMed ID: 31085352
[TBL] [Abstract][Full Text] [Related]
10. Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling.
van Dinther M; Zhang J; Weidauer SE; Boschert V; Muth EM; Knappik A; de Gorter DJ; van Kasteren PB; Frisch C; Mueller TD; ten Dijke P
PLoS One; 2013; 8(4):e62295. PubMed ID: 23638027
[TBL] [Abstract][Full Text] [Related]
11. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
[TBL] [Abstract][Full Text] [Related]
12. In silico discovery of quinoxaline derivatives as novel LRP5/6-sclerostin interaction inhibitors.
Choi J; Lee K; Kang M; Lim SK; Tai No K
Bioorg Med Chem Lett; 2018 Apr; 28(6):1116-1121. PubMed ID: 29486968
[TBL] [Abstract][Full Text] [Related]
13. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D
J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503
[TBL] [Abstract][Full Text] [Related]
14. The role of the Wnt signaling pathway in osteoblast commitment and differentiation.
Yavropoulou MP; Yovos JG
Hormones (Athens); 2007; 6(4):279-94. PubMed ID: 18055419
[TBL] [Abstract][Full Text] [Related]
15. Lrp5 and Lrp6 exert overlapping functions in osteoblasts during postnatal bone acquisition.
Riddle RC; Diegel CR; Leslie JM; Van Koevering KK; Faugere MC; Clemens TL; Williams BO
PLoS One; 2013; 8(5):e63323. PubMed ID: 23675479
[TBL] [Abstract][Full Text] [Related]
16. [Hormones and osteoporosis update. Mechanisms of anabolic and catabolic effects of PTH on bone].
Kobayashi T
Clin Calcium; 2009 Jul; 19(7):911-8. PubMed ID: 19567985
[TBL] [Abstract][Full Text] [Related]
17. Sclerostin blockade promotes bone metastases of Wnt-responsive breast cancer cells.
Hiraga T; Horibe K; Koide M; Yamashita T; Kobayashi Y
Cancer Sci; 2023 Jun; 114(6):2460-2470. PubMed ID: 36840409
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition.
Boschert V; van Dinther M; Weidauer S; van Pee K; Muth EM; Ten Dijke P; Mueller TD
PLoS One; 2013; 8(11):e81710. PubMed ID: 24312339
[TBL] [Abstract][Full Text] [Related]
19. Cajanolactone A from
Liu S; Luo ZH; Ji GM; Guo W; Cai JZ; Fu LC; Zhou J; Hu YJ; Shen XL
Molecules; 2019 Jan; 24(2):. PubMed ID: 30642055
[TBL] [Abstract][Full Text] [Related]
20. The regulation of osteoclast differentiation by Wnt signals.
Kobayashi Y; Uehara S; Koide M; Takahashi N
Bonekey Rep; 2015; 4():713. PubMed ID: 26157576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
